DEF: Creative Medical Technology Holdings Seeks Stockholder Approval for Warrant Exercise to Comply with Nasdaq Listing Rules

Creative Medical Technology Holdings is holding a special meeting on May 5, 2025, to seek stockholder approval for the exercise of warrants covering 1,799,774 shares of common stock to comply with Nasdaq Listing Rule 5635(d).

Summary

• Creative Medical Technology Holdings is convening a special meeting of stockholders on May 5, 2025, to vote on a proposal to approve the exercise of warrants to purchase 1,799,774 shares of common stock.
• The warrants were issued on March 6, 2025, and include inducement warrants issued to holders of existing warrants and a warrant issued to Roth Capital Partners, LLC, the company's advisor.
• The exercise price of the warrants is $3.75 per share.
• Approval is required to comply with Nasdaq Listing Rule 5635(d), as the warrant exercise would result in the issuance of more than 20% of the company's outstanding common stock at a price less than the minimum price.
• Failure to obtain stockholder approval would require the company to hold additional meetings every 90 days, incurring substantial costs.
• As of March 6, 2025, there were 2,323,428 shares of common stock outstanding, held by 79 holders of record.
• The Board of Directors unanimously recommends voting FOR the approval of the warrant exercise.
• The company has agreed to file a registration statement with the SEC to register the resale of the shares of Common Stock underlying the Warrants under the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining the need for a stockholder vote. While the warrant exercise could be beneficial for the company, it also carries the risk of dilution. The sentiment is neutral to slightly positive.

Positives

• Approval of the warrant exercise will allow the company to comply with Nasdaq Listing Rule 5635(d).
• Avoiding repeated stockholder meetings will save the company substantial costs, including legal and proxy-related expenses.
• The Board of Directors unanimously recommends a vote FOR the proposal, indicating their belief that it is in the best interest of the company and its stockholders.

Negatives

• Exercise of the warrants will dilute the ownership interest of existing stockholders.
• The sale of shares upon warrant exercise could adversely affect the market price of the company's common stock.
• Failure to approve the proposal will result in the company incurring substantial costs for holding additional meetings every 90 days.

Risks

• Stockholder disapproval of the warrant exercise could lead to repeated special meetings and increased costs.
• The potential dilution of existing stockholders' ownership and the possible negative impact on the stock price are risks associated with the warrant exercise.
• The company is dependent on stockholder approval to proceed with the warrant exercise.

Future Outlook

The company is seeking stockholder approval to proceed with the warrant exercise. Failure to obtain approval will necessitate additional meetings every 90 days until approval is secured.

Management Comments

• Timothy Warbington, Chief Executive Officer, urges stockholders to vote as soon as possible via the Internet, telephone, or mail.
• The Board has determined that allowing the holders of the Warrants to exercise the Warrants in full is in the best interest of the Company and its stockholders because the Company is required to obtain the approval its stockholders to such exercise and to repeatedly call stockholders meetings every 90 days until such stockholder approval is obtained.

Industry Context

Many companies use warrants as part of their financing strategies, and Nasdaq Listing Rule 5635(d) is a standard requirement to protect shareholder interests when significant dilution may occur. Seeking stockholder approval for warrant exercises is a common practice to ensure compliance and transparency.

Comparison to Industry Standards

• The need to obtain shareholder approval for issuing more than 20% of outstanding shares at a price below market value is a common requirement across Nasdaq-listed companies.
• Other companies, such as [Comparable Company A] and [Comparable Company B], have faced similar requirements when issuing a significant number of shares or warrants.
• The specific terms of the warrants, such as the exercise price and duration, are within the typical range observed in similar financing transactions.

Stakeholder Impact

• Existing stockholders face potential dilution of their ownership interest.
• The market price of the company's common stock could be affected by the sale of shares upon warrant exercise.
• The company will incur costs associated with holding the Special Meeting.

Next Steps

• Stockholders need to vote on the proposal to approve the warrant exercise.
• The company will hold the Special Meeting on May 5, 2025.
• The company will file a Current Report on Form 8-K with the SEC to disclose the voting results within four business days after the Special Meeting.

Key Dates